Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
Stanford University
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
University of Washington
National Cancer Institute (NCI)
Icahn School of Medicine at Mount Sinai
Case Comprehensive Cancer Center